Needham & Company LLC Lowers CorMedix (NASDAQ:CRMD) Price Target to $15.00

CorMedix (NASDAQ:CRMD) had its price objective cut by equities researchers at Needham & Company LLC from $16.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target would indicate a potential upside of 99.73% from the stock’s previous close.

CRMD has been the topic of several other reports. HC Wainwright upped their price objective on shares of CorMedix from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, October 8th. Zacks Research upgraded CorMedix from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 4th. Truist Financial set a $16.00 price objective on CorMedix in a research note on Thursday. Finally, D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of CorMedix in a research note on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $17.86.

CorMedix Stock Performance

NASDAQ:CRMD opened at $7.51 on Thursday. The company’s 50-day moving average is $11.03 and its two-hundred day moving average is $11.68. CorMedix has a 1-year low of $5.60 and a 1-year high of $17.43. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.94 and a quick ratio of 1.73. The firm has a market capitalization of $591.71 million, a price-to-earnings ratio of 3.65 and a beta of 1.36.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.78. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The business had revenue of $104.28 million during the quarter, compared to analysts’ expectations of $65.63 million. During the same period in the prior year, the business posted ($0.05) EPS. The company’s revenue was up 810.2% compared to the same quarter last year. Analysts forecast that CorMedix will post -0.32 EPS for the current year.

Insider Buying and Selling

In other CorMedix news, Director Steven W. Lefkowitz sold 40,000 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the sale, the director owned 80,498 shares in the company, valued at $956,316.24. This represents a 33.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Joseph Todisco sold 30,000 shares of CorMedix stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $12.00, for a total value of $360,000.00. Following the completion of the transaction, the chief executive officer owned 509,496 shares of the company’s stock, valued at $6,113,952. The trade was a 5.56% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 90,000 shares of company stock valued at $1,095,200. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. raised its holdings in shares of CorMedix by 17.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock valued at $81,000 after purchasing an additional 998 shares in the last quarter. Russell Investments Group Ltd. raised its stake in CorMedix by 22.2% in the second quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock valued at $81,000 after buying an additional 1,190 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in CorMedix by 11.9% in the second quarter. China Universal Asset Management Co. Ltd. now owns 13,622 shares of the company’s stock valued at $168,000 after buying an additional 1,451 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in CorMedix by 5.3% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 29,114 shares of the company’s stock worth $338,000 after buying an additional 1,478 shares during the last quarter. Finally, Palisades Investment Partners LLC boosted its position in shares of CorMedix by 0.3% during the 3rd quarter. Palisades Investment Partners LLC now owns 564,106 shares of the company’s stock worth $6,561,000 after acquiring an additional 1,579 shares in the last quarter. Institutional investors and hedge funds own 34.18% of the company’s stock.

Key CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 results were strong: Q4 net revenue ~ $127M, pro forma FY‑2025 revenue ~ $400M, Q4 adjusted EBITDA $77–81M and cash/short‑term investments ~ $148M — these numbers support near‑term profitability and cash runway. CorMedix Preliminary Q4 and FY‑2025 Results
• Positive Sentiment: Management continuity: CEO Joseph Todisco extended his employment agreement and will assume the Chairman role (with Myron Kaplan becoming Lead Independent Director) — reduces uncertainty about strategic direction. Leadership and Board Updates
• Positive Sentiment: At least one broker (D. Boral Capital) reaffirmed a “buy” with a $14 price target, signaling some analysts still see substantial upside from current levels. D. Boral Capital Rating
• Neutral Sentiment: Broader coverage and analysis pieces are re‑evaluating valuation after the guidance shift and recent Q3/Q4 disclosures; these stories summarize drivers but are informational rather than action‑triggering. Valuation After Guidance Shift
• Negative Sentiment: FY‑2026 revenue guidance was cut to $300–320M versus consensus near ~$445M — a large shortfall that directly prompted the sell‑off as investors reprice growth expectations. Guidance Cut and Market Reaction
• Negative Sentiment: Market reaction and headlines: multiple outlets report sharp intraday declines and investors asking whether to buy the dip — reflects forced/near‑term selling and sentiment risk even with solid recent results. Why CRMD Is Crashing

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.